Bloom Surgical is revolutionizing laparoscopic surgery with LaparoVision, a novel origami-inspired “windshield wiper” for laparoscopes. Unlike current solutions, LaparoVision effectively wipes and irrigates the lens directly at the surgical site, ensuring continuous clarity without scope removal.

Freyya is a femtech medical device company transforming pelvic floor care for the 1 in 4 women living with pelvic floor disorders. The Freyya device is the first wearable, intra-vaginal biosensor that measures pelvic floor muscle force and intra-abdominal pressure during real-life activity, delivering real-time biofeedback to a mobile app and clinicians.

DigiBeat has simplified the operation of cardiac screening to the point that medical assistance, and even at-home patients, can operate it. Expanding access to real cardiac care from specialists and hospitals to family doctors and patient homes through AI and smart automations.

At Path Fertility, we built SpermQT: the first clinically validated epigenetic sperm quality test. We measure sperm function, not just count and motility, giving physicians data that predicts success across fertility treatments.

Microvascular Therapeutics is developing a next-generation microbubble contrast agent, CardiSon, for diagnostic ultrasound, designed to set a new standard in image quality, ease of use, and safety. CardiSon is a platform for nanobubble therapies, combining imaging and therapy, with broad applications across oncology, cardiovascular disease, and neurology.

Purgo Scientific is developing a first-in-class refillable drug delivery device called the Purgo Pouch that sustains local, high-dose antibiotic therapy in surgical sites. It received Breakthrough Device Designation by the FDA, addressing the major unmet need of fracture-related infection treatment.

Full IND preclinical readiness FDA package without sacrificing one animal.

Numiera Therapeutics is developing small-molecule drugs for oncology indications by targeting a key metabolic vulnerability in cancer cells. Our first-in-class CPT1 inhibitor has received FDA orphan drug designation, on the basis of independently-replicated preclinical efficacy data from five different labs.

Glafabra’s Live-cel(TM) gene therapy provides patients with a highly effective and redosable treatment, where one dose lasts for years, not weeks. Our lead asset in Fabry disease competes against a standard of care that is expensive, burdensome, and incomplete.

Intactis Bio offers biocomputation as a service to the AI/ML industry for low-energy computation, with true biological intelligence.

MyxTek Bio is a next‑generation biomaterials company commercializing Utah State University’s patented hagfish protein technology to create high‑performance protein membranes for advanced cell culture.

Eyescreen is revolutionizing preclinical drug development for ophthalmology by bridging the critical gap between traditional animal models and human clinical trials.